Status:
TERMINATED
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study avai...
Detailed Description
The study terminated on 08MAR2016 as it met its objectives of characterizing long term safety and tolerability. The study did not terminate due to safety concerns.
Eligibility Criteria
Inclusion
- Have participated in qualifying study with CP-690,550 and are 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris).
Exclusion
- Non-plaque or drug induced forms of psoriasis;
- Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB).
- Any uncontrolled significant medical condition.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
2867 Patients enrolled
Trial Details
Trial ID
NCT01163253
Start Date
September 1 2010
End Date
June 1 2016
Last Update
June 26 2017
Active Locations (323)
Enter a location and click search to find clinical trials sorted by distance.
1
Radiant Research, Inc.
Birmingham, Alabama, United States, 35209
2
UAB Dermatology
Birmingham, Alabama, United States, 35233
3
Horizon Research Group, Inc.
Mobile, Alabama, United States, 36608
4
Radiant Research, Inc.
Tucson, Arizona, United States, 85712